Although our understanding of CystC function in regulating TGF-β signaling is in its infancy, our findings suggest that this protease inhibitor might provide an innovative model for the development of novel TβR-II antagonists designed to combat the stimulation of tumor progression and EMT by TGF-β. The gene discussed is TGFB1; the disease is neoplasm.